Teneligliptin

Teneligliptin has been studied in 7 papers since 2018: 2 trials and 2 observational studies in people, 2 in animals, 1 review; 2 in the past year. The newest paper, Nov 14, 2026: “Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial”.

Intervention

7 papers study it8 findingsUpdated

1 new paper in 30 daysSee all 7 papers on teneligliptin

At a glance

Independent labs found the same change in people. 3 independent labs in 2 countries; 21 trials, 8 about aging, 10 with no results posted.

“At week 24, the teneligliptin group showed a significant reduction in HbA1c compared with the placebo group”
Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trialJournal of diabetes investigation2026doi:10.1111/jdi.70491

None of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 2 countries
  • 21 trials, 8 about aging, 10 with no results posted
  • Funder: Handok
  • 6 of 7 findings with company ties
  • 21 of 21 trials sponsored by its developers
  • Human trial2
  • Humans2
  • Animals2

Studies in people

2 studies gave teneligliptin to people and measured what changed.

What changedDesignPeopleSource

down: Decreases HbA1cLeast-squares mean difference −0.69 percentage points; 95% CI −0.83 to −0.54

no change: Has no effect on treatment-emergent adverse events

Randomized trial24 weeks119 peopleKorean patients with type 2 diabetes inadequately controlled with empagliflozin and metforminJournal of diabetes investigation, Nov 14, 2026

down: Decreases HbA1c-0.76% (95% CI, -1.08 to -0.44)

up: Increases TIR70-18013.3% (95% CI, 6.0 to 20.6)

down: Decreases glycemic variability

Randomized trial12 weeks65 people≥65 yearsOlder adults; elderly type 2 diabetes mellitusDiabetes & metabolism journal, Jun 16, 2021

What did studies of teneligliptin find?

7

Studies of teneligliptin measured 7 outcomes, among them HbA1c, treatment-emergent adverse events and type 2 diabetes.

HbA1c

downin humans2

2 studies
  1. Teneligliptin decreases HbA1c in humans (Least-squares mean difference −0.69 percentage points; 95% CI −0.83 to −0.54).

    Human trialKorean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin; compared with placebo20 mg once daily24 weeks

  2. Teneligliptin decreases HbA1c in humans (elderly type 2 diabetes mellitus) (-0.76% (95% CI, -1.08 to -0.44)).

    Human trialelderly type 2 diabetes mellitus20 mg12 weeksn = 65

More on HbA1c

Treatment-emergent adverse events

no changein humans1

1 study
  1. Teneligliptin showed no clear effect on treatment-emergent adverse events in humans.

    Human trialKorean patients with type 2 diabetes receiving empagliflozin and metformin; compared with placebo20 mg once daily24 weeks

Type 2 diabetes

downin humans1

1 study
  1. Teneligliptin decreases type 2 diabetes in humans.

    Review

More on Type 2 diabetes

Hypoglycemia

no changein humans1

1 study
  1. Teneligliptin showed no clear effect on hypoglycemia in humans (elderly type 2 diabetes mellitus).

    Human trialelderly type 2 diabetes mellitus20 mg12 weeksn = 65

More on Hypoglycemia

Glycemic variability

downin humans1

1 study
  1. Teneligliptin decreases glycemic variability in humans (elderly type 2 diabetes mellitus).

    Human trialelderly type 2 diabetes mellitus20 mg12 weeksn = 65

More on Glycemic variability

TIR70-180

upin humans1

1 study
  1. Teneligliptin increases TIR70-180 in humans (elderly type 2 diabetes mellitus) (13.3% (95% CI, 6.0 to 20.6)).

    Human trialelderly type 2 diabetes mellitus20 mg12 weeksn = 65

More on TIR70-180

Skeletal muscle mass

no changein humans1

1 study
  1. Teneligliptin showed no clear effect on skeletal muscle mass in T2DM patients on hemodialysis (18.6 kg to 18.9 kg, P = 0.16).

    Human trialin T2DM patients on hemodialysissix monthsn = 10

Has teneligliptin been tested in people?

8 of 21 about aging

Yes: 2 trials and 2 observational studies in people have been published.

Who is developing teneligliptin?

2 companies: Tanabe Pharma and Handok.

Companies

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 12 papers in 12 months